Fired SpaceX employee with Crohn's disease says bosses timed his bathroom breaks
A former SpaceX employee who suffers from Crohn's disease claims supervisors monitored his restroom use, timing each toilet break and issuing a formal reprimand if he wasn't back within 10 minutes.
That's according to a federal discrimination lawsuit obtained by The Independent, which says Douglas Altshuler's gastrointestinal condition makes it impossible for him to last more than 35 to 45 minutes without a trip to the lavatory – meaning as many as 14 times over the course of an eight-hour shift.
But not only would the 58-year-old Altshuler be disciplined for taking longer than his bosses deemed necessary, they brazenly 'threatened termination if [he] used the bathroom too often,' the lawsuit contends.
People living with Crohn's 'often suffer from debilitating urgency to use a restroom immediately, or risk having an embarrassing accident,' according to the nonprofit Crohn's & Colitis Foundation.
After Altshuler went to management about the issue, complete with a doctor's note outlining his debilitating ailment, his suit says they dismissed his grievance as 'unsubstantiated.' When Altshuler pushed back on the seeming lack of concern for his physical well-being, the suit says he was subsequently let go for 'alleged deficient performance.'
Altshuler's suit also takes aim the Elon Musk owned SpaceX's business and safety practices, accusing the company of denying him proper meal breaks, shorting his pay, exposing him to toxic chemicals, and, in one instance that he reported to both state and federal authorities, he 'witnessed industrial parts being dried in the kitchen oven where employees cook their food.'
Lawyer Clive Pontusson, a former trial attorney for the U.S. Equal Employment Opportunity Commission, is representing Altshuler in the case. He said SpaceX has 'a legal responsibility' to accommodate workers' disabilities.
The law says that an employee has a right to ask their employer for a reasonable accommodation for a disability, 'without fear that their job will be threatened or taken away,' Pontusson told The Independent.
'The law also says that employees should be able to raise concerns about workplace safety without fear of retaliation,' he said, noting that government regulators 'eventually substantiated many of Mr. Altshuler's concerns about an unsafe work environment at SpaceX.'
A SpaceX spokesperson and the attorney defending the company against Altshuler's lawsuit did not respond to requests for comment.
Altshuler began working at SpaceX, one of the numerous entities headed up by Musk, the erratic billionaire and Donald Trump's 'First Buddy,' on June 2023, where he was assigned to answer customer support calls at its Redmond, Washington, facility, according to his complaint. The Redmond campus includes a factory where components are assembled for Starlink, the SpaceX unit that provides mobile broadband service by way of a network of satellites put into orbit aboard the company's rockets.
The job seemed fine until early 2024, when Altshuler's supervisor 'began tracking Mr. Altshuler's bathroom breaks and repeatedly criticized [him] for using the bathroom,' the complaint states.
In response, it says Altshuler provided the supervisor with a letter from his physician requesting a reasonable accommodation due to his Crohn's, namely, permission to use the bathroom every 35 to 45 minutes. The supervisor acknowledged that Altshuler had a legitimate disability, and assured him that 'he would never restrict [his] restroom use,' the complaint continues.
Further, it goes on, a second manager gave Altshuler his word that the company would not 'question or track his bathroom usage.'
The SpaceX Human Resources department followed up by asking Altshuler to fill out reasonable accommodation request forms, according to the complaint. However, since Altshuler had been informed by supervision that he would be free to use the toilet as needed, the complaint says he told HR that he did not need to formalize things 'because leadership confirmed that his bathroom use would not be restricted.'
Yet, according to Altshuler, the fragile peace didn't hold for long. His supervisor soon went back to monitoring his bathroom breaks, and, the complaint alleges, would give Altshuler an 'occurrence' – that is, an adverse write-up – if he was away from his desk for more than 10 minutes, the complaint states. So Altshuler went to his boss's bosses to report his ongoing predicament, according to the complaint.
They asked for details, which Altshuler provided in an email, the complaint says. Still, it alleges, higher-ups 'responded with confusion.'
When it came time for Altshuler's next performance review, his 'threatening and argumentative' supervisor, apparently upset over Altshuler having escalated the bathroom matter up the chain of command, allegedly retaliated by giving him an unsatisfactory appraisal that included 'alleged performance deficiencies which were never brought to [Altshuler's] attention before,' the complaint states.
In October 2024, Altshuler was reassigned to a new supervisor, according to the complaint. Nevertheless, it says his old supervisor still continued to listen in on Altshuler's customer calls throughout the day and kept watch over his support tickets. It felt to Altshuler that he was being bullied, so he again notified HR about what was going on, the complaint states.
That November, Altshuler was forced to file a workers' compensation claim and take three weeks of medical leave due to a debilitating 'chemical exposure' on the job, according to the complaint, which says he then notified the U.S. Occupational Safety and Health Administration (OSHA) about the incident. Altshuler also told OSHA and the Washington Department of Labor and Industries about the SpaceX employee he claimed to have seen drying industrial components in the breakroom oven, the complaint states.
When Altshuler returned to work, bathroom visits once again became a point of contention, his complaint alleges. This time, it says, Altshuler's new supervisor threatened to fire him if he used the toilet 'too often.'
In mid-December, Altshuler went to the head of HR with his grievances, according to the complaint. He had now been working at SpaceX for some 18 months, and his managers were still making his life miserable on a constant basis, the complaint states.
It says Altshuler additionally revealed to HR that he, in fact, was the one who had informed government regulators about the alleged safety problems.
On January 6, 2025, HR emailed Altshuler with their findings, telling him that 'his concerns… were unsubstantiated,' according to the complaint. The same day, he contacted SpaceX's HR chief, upset that the company had 'dismissed his claims as being without merit despite the evidence he presented,' the complaint says.
Three days later, SpaceX fired Altshuler for 'deficient performance,' according to the complaint.
The multiple grievances Altshuler reported to SpaceX 'regarding discrimination, retaliation and safety issues, [his] request for reasonable accommodation, and [his] workers' compensation claim were motivating factors in the decision to terminate [his] employment,' the complaint states.
It says the ordeal caused Altshuler mental anguish, humiliation, pain and suffering, and loss of enjoyment of life.
Broadly speaking, Pontusson, Altshuler's attorney, told The Independent, 'The company's actions are egregious and in clear violation of the law. Mr. Altshuler intends to seek all legal remedies that are available to him.'
Altshuler is now seeking economic damages for back pay, front pay, lost benefits, and medical expenses in an amount to be determined by a jury, along with actual, compensatory, consequential, incidental and exemplary damages for disability discrimination, retaliation, failure to accommodate, wrongful termination and negligent infliction of emotional distress.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
26 minutes ago
- Associated Press
New online tool helps women on Medicaid find prenatal care and family planning
At the University of Mississippi Medical Center, one researcher's full-time job for the past nine months has been to find out which clinics around the state offer different kinds of women's health care, and whether they accept various forms of Medicaid. The final result is a recently launched database aimed at helping women locate the nearest clinic that can offer the care they need. The work that went into creating it highlights a pervasive problem: Even making an appointment can be a barrier that keeps women from improving their lives. 'We Need to Talk' is a compilation of all Mississippi clinics offering prenatal care – specifying which ones also offer family planning, and whether they take Medicaid insurance, Medicaid waivers and see women whose Medicaid applications are pending. There is also a hotline designed to give additional support to anyone having questions or feeling overwhelmed about the process. 'Having gone through the work, it was remarkable. It wasn't easy to figure out where you should go for care,' said Dr. Thomas Dobbs, former state health officer and dean of the John D. Bower School of Population Health at UMMC, who oversaw the project. 'And that should be one of the most basic bits of information we have.' The idea was born from the recent 900% increase in babies born with syphilis, Dobbs explained, which he called a 'canary in a coal mine' signaling more danger to come. An investigation into the epidemic showed that one of the driving factors was delayed prenatal care, caused in large part by inaccessible information and concerns about cost, Dobbs said. Finding reproductive and prenatal care can be difficult for several reasons. For one thing, there are many different kinds of clinics in Mississippi, making it hard for patients to know what to search for. The list includes federally qualified health centers, county health department clinics and private OB-GYNs. Another reason is that many clinics don't specify online whether they take Medicaid, much less what their policy is on specific or temporary Medicaid coverage. Calling doesn't always guarantee patients a comprehensive or accurate answer. The new database is an initiative of UMMC's Myrlie Evers-Williams Institute – housed in the Jackson Medical Mall – which is committed to eliminating health disparities by studying the intersection of health and social issues. The institute has a clinic on site that practices what's called 'social medicine,' a key element of eliminating those disparities, the institute's executive director Victoria Gholar explained. 'If you have a patient who has asthma and they're living in a situation where mold is in their environment, it will really be hard for them to get better,' Gholar said. 'Or, if we have a patient who has to use an electronic (medical) device, and their electricity is no longer available because they weren't able to take care of their utility bill, then we try to work with them and connect them to resources that might be able to help.' The institute employs a wide range of professionals who work on health from a non-clinical standpoint, such as researchers, community engagers, social workers and registered dietitians. It hosts events like food drives and offers free support from budgeting strategies to meal preparation for those with conditions like diabetes or high blood pressure. Aside from knowing what to search for, finding clinics that accept Medicaid can also be complicated because Mississippi Medicaid eligibility is constantly changing for a woman based on her age and circumstance – what kinds of services she's seeking, as well as whether she's pregnant. Medicaid eligibility in Mississippi is among the strictest in the nation, with one exception – pregnant women. That means many low-income women only become eligible for Medicaid once pregnant. And since an application can take up to eight weeks to be processed, the chances that a woman in this situation will be able to use her newly acquired Medicaid insurance in the first trimester are slim. A law that would cut out this interim period and allow low-income pregnant women to be immediately seen by a doctor passed the Legislature in 2024, but was never implemented because of legislative errors. The policy went back through the Legislature in 2025, passed overwhelmingly again, but is not yet in effect. Some doctors already see women whose Medicaid application is pending, and the UMMC tool specifies at which clinics that's the case. Women of reproductive age seeking reproductive health care are also eligible for leniency in the typical Medicaid stipulations. These women can apply for a Medicaid family planning waiver, which allows them to access Medicaid for family planning purposes, even if they don't qualify for general Medicaid coverage. The income requirement for pregnancy Medicaid and the family planning waiver is a household income of less than 194% of the federal poverty level, or about $2,500 a month for one person in 2025. Dobbs, who has been the main point person on the project, said he hopes the online database is one more resource improving health care accessibility and women's health metrics in Mississippi. 'This isn't about getting patients to UMMC at all,' Dobbs said. 'It's about empowering patients to be able to get the care they need where they live.' ___ This story was originally published by Mississippi Today and distributed through a partnership with The Associated Press.
Medscape
32 minutes ago
- Medscape
A PCP Guide to Emerging Therapies for Resistant Hypertension
This transcript has been edited for clarity. Matthew F. Watto, MD: Welcome back to The Curbsiders . I'm Dr Matthew Frank Watto, here with my great friend and America's primary care physician, Dr Paul Nelson Williams. Paul, this is a topic you know a ton about, isn't it? Paul N. Williams, MD: It's one I always have questions about; I think this is our 37th episode on high blood pressure, if I'm not mistaken. Watto: The audience can't get enough of it — turns out, neither can I. Williams: Me neither! Watto: I love talking about high blood pressure, and this was with a great guest, Dr Jordy Cohen. She's a hypertension expert and a nephrologist. Paul, to start us off, what are we doing with blood pressure cuffs these days? Those manual ones on the wall, those are the way to go, right? Williams: This is a scenario we talk about all the time, and we've beat this drum a lot in prior episodes. I think we've all experienced a patient whose initial triage blood pressure reading is elevated, and either you or the patient will ask for a recheck and you're tempted to use a blood pressure cuff that's been hanging on the wall, has not been calibrated in 17 years, has a decaying spiral cord, and looks like it would fall apart if you touched it. Turns out that's probably not the best way to do it, Matt. So, to reiterate: Automated cuffs are the preferred option. They are more accurate. In this episode with Dr Cohen, we talked about making sure we use the appropriate cuff size and when we have patients who have large arms, you may have to use a wrist measurement every so often. In these circumstances, positioning matters: feet flat, back supported, elbow resting on a table, and have two fingers on the opposite clavicle so that everything is at heart level. If you're taking the blood pressure reading using a cuff around the arm itself, again, you should make sure the patient's arm is resting on a tabletop, bedside, or even on your own arm to ensure it's at heart level. You also shouldn't talk with the patient during that process so you can give them every chance to have an accurate blood pressure reading. That's the first thing: Get an accurate reading. Then everything else follows that step, as you should only treat a diagnosis that you've appropriately made. Watto: All the goals are based on a properly taken blood pressure, so if your patient's blood pressure hasn't been appropriately measured, you might overtreat or undertreat someone. For most patients who are nonfrail, we're now shooting for a blood pressure that is below 130/80 mm Hg. The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for patients with chronic kidney disease state that normal blood pressure should be below 120/80, which is very hard to do. If we're getting people with a systolic in the 120s, that's probably about as good as we're going to get. For treatment, Dr Cohen and I have adopted this practice of using combination pills for hypertension management — either a calcium-channel blocker with an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker (ARB). I usually prefer a calcium-channel blocker with an ARB or the 'triple pill,' a single-pill combination of a calcium-channel blocker, an ARB, and a diuretic. That's what I go to now as my first-line agent. I'm using a lot of either low-dose or medium-dose combination therapy. I don't usually go to the highest dose unless I'm in a situation where I have to decide between starting a fourth medication or going to a higher dose. That's really been a practice change for me. Dr Cohen reiterated that point and emphasized that it's easiest for the patient and they usually experience fewer side effects when you choose a low-to-moderate dose in comparison to a high dose. Williams: It's a point that we've made in prior episodes, as well. As you start to max out the doses of these medications, you get diminishing returns in terms of their efficacy in lowering blood pressure efficacy and patients can start to experience increased side effects. It's a far better option to start with a kind of median dose as opposed to really trying to crank up the dose, because you just don't get that much more benefit with that approach. Watto: We're going to discuss some of the newer blood pressure–lowering agents. Paul, the first one I want to ask you about is not quite a blood pressure medication, but it does lower blood pressure. Which medication am I talking about here? Williams: I think you're probably referring to semaglutide, Matt. I think we all have a fair amount of comfort with these diabetes and weight loss medications. These are remarkable medications and the indications keep piling on, which is great. Semaglutide, in particular, is not approved for hypertension, but it does lower blood pressure, likely as a result of the weight loss that is achieved with the medication. So, it's not technically an antihypertensive, but it provides a great blood pressure benefit. I think there's also some 'fancy pants' medications coming down the pipeline that we should probably be aware of, right? Watto: Yes, and the first one I'll mention is endothelin receptor antagonists. As a generalist, you're probably not going to be prescribing these; they will probably be prescribed by a hypertension specialist. Compared with placebo, they have a modest effect in lowering blood pressure (~4 mm Hg), but they are officially approved, so they're out there. What's more exciting, Paul, are aldosterone synthase inhibitors. The generic names for these include baxdrostat and lorundrostat. They're not yet approved, but I believe they are in phase 2 or phase 3 trials, depending on the indications. They seem promising, as they have a much stronger effect on blood pressure (~10-15 mm Hg) compared with placebo. Dr Cohen thinks these medications are probably going to be in the primary care wheelhouse soon. Cost will probably an issue with these medications at the start, but otherwise, these are pills that are taken once a day and they don't have the antiandrogen side effects that you can get with the mineralocorticoid receptor antagonists (MRAs), like spironolactone. Dr Cohen was really excited about being able to prescribe these at some point. Williams: And the MRAs are traditionally a fourth-line medication (unless you have compelling indications), so to have something else in your armamentarium that has less side effects is super exciting. It'll be great to see these in the pipeline. Watto: Now, what would you say, Paul, if I told you there was a medication for blood pressure that is only administered once every 6 months and will shut down the renin-angiotensin-aldosterone system (RAAS)? How does that sound? Williams: As someone who's taken medical school physiology, it sounds lightly terrifying! It feels like you do need the RAAS for some things, but I think for patients that are less interested in taking medications — which turns out to be most patients — it could potentially be exciting. I think as long as we have a way to reverse the effects of this medication if needed, then I think there's potential for excitement around this medication. Watto: I'm of course talking about a small interfering RNA (siRNA) agent. The one we talked about in this episode was zilebesiran; it's an siRNA agent and is administered once every 6 months. But no one would feel comfortable giving this unless there's an antidote, because if a patient gets septic, they probably need their RAAS to help them out there. Williams: Or if you have a patient who is pregnant — lots of reasons why you might actually want that system working. Watto: Exactly. Now, some people just don't want to take medications even if they need them, Paul. What else might be offered to a patient with high blood pressure? And how excited should we be about this next therapy? Williams: I feel like you're asking the wrong guy, Matt! I think you're alluding to renal denervation therapy. I feel it had a lot of wild enthusiasm initially, then it kind of waned, and now I feel like enthusiasm is back, baby — we're back into renal denervation. It sounds like a great option and I think we're doing a little better job with it, but its effect on lowering blood pressure is about equivalent to the effect you observe with a single-agent medication. So, realistically, these patients may still need to be on medications for blood pressure control. It's only effective for about two thirds of patients who get the procedure; that's 33% of your patients who would go through this invasive procedure where we're frying a nerve and in the end, they may not actually experience any blood pressure benefit. I think there's still a population that would benefit from and be interested in this option, but I don't think it's something that we should consider as first-line therapy for the majority of folks because of that potential for treatment failure and the continued need for medications among a substantial portion of the patients who undergo this procedure. It's still exciting that there's evidence for it and it does cause significant blood pressure lowering, so it's nice to have another option. Watto: Yeah, and I think patients are going be coming in and asking about it, so having some knowledge about the pros and cons of the procedure is important.
New York Times
32 minutes ago
- New York Times
Palantir's Collection of Disease Data at C.D.C. Stirs Privacy Concerns
The Centers for Disease Control and Prevention's plans to consolidate data on diseases like measles and polio are raising concerns about patient privacy, delays in spotting long-term trends and ways the Trump administration may use the information. The agency told state officials earlier this week that it would shift disease information to a new system managed by Palantir, the data analysis and technology firm co-founded by Peter Thiel. The change is not entirely unexpected. The Covid pandemic revealed that the C.D.C.'s data systems were antiquated, hobbling the country's response in the crucial early months. A plan to modernize and consolidate the agency's data systems began during the Biden administration. But news that the Trump administration has expanded Palantir's work across the federal government in recent months, allowing it to compile detailed information about Americans, has introduced a new layer of anxiety and mistrust among state and local officials about sharing data with the C.D.C. Palantir's systems, including those at the C.D.C., rely on a platform called Foundry that could merge information from different agencies. The Department of Health and Human Services, the Food and Drug Administration and the National Institutes of Health all use Foundry. Some officials worry that a sprawling data collection system could expose or endanger people with sensitive health needs, like gender care, reproductive health care or disabilities. Some labor and other advocacy groups have tried to block the Trump administration from sharing data across agencies. Want all of The Times? Subscribe.
